Experimental drug ampligen takes on pancreatic cancer in new trial
NCT ID NCT05494697
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding the experimental drug Ampligen to standard care can help people with locally advanced pancreatic cancer that hasn't spread. About 90 participants who have completed at least four months of initial chemotherapy will receive either Ampligen plus standard care or standard care alone. The main goal is to see if the combination delays tumor growth and improves survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ampligen (rintatolimod)
What this could lead to
If successful, this could provide a new treatment option to help control locally advanced pancreatic cancer and extend survival when used after initial therapy.
What could go wrong
This is an early-phase trial with only 90 participants, and the study is currently suspended. The drug may not improve outcomes or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gabrail Cancer Center Research
Canton, Ohio, 44718, United States
-
Nebraska Medical Center
Omaha, Nebraska, 68198, United States
-
Virginia Mason Medical Center
Seattle, Washington, 98101, United States